Pfizer’s accord with the Trump administration, securing a three-year tariff grace period amid commitments to expand U.S. manufacturing and apply most favored nation (MFN) pricing to Medicaid drugs, catalyzed a 14% jump in shares. The company announced plans to invest $70 billion in domestic manufacturing and R&D, aiming to bolster U.S. biopharmaceutical leadership. Pricing pledges include significant discounts on top-selling drugs and direct-to-consumer sales via an upcoming platform named TrumpRx.gov, emphasizing affordability and supply chain sovereignty.